RT Journal Article
SR Electronic
T1 Association of Time Course of Thrombectomy and Outcomes for Large Acute Ischemic Region: RESCUE-Japan LIMIT Sub-Analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.15.23287338
DO 10.1101/2023.03.15.23287338
A1 Ishihara, Hideyuki
A1 Nishimoto, Takuma
A1 Shimokawa, Mototsugu
A1 Oka, Fumiaki
A1 Sakai, Nobuyuki
A1 Yamagami, Hiroshi
A1 Toyoda, Kazunori
A1 Matsumaru, Yuji
A1 Matsumoto, Yasushi
A1 Kimura, Kazumi
A1 Ishikura, Reiichi
A1 Inoue, Manabu
A1 Uchida, Kazutaka
A1 Sakakibara, Fumihiro
A1 Morimoto, Takeshi
A1 Yoshimura, Shinichi
A1 the RESCUE Japan LIMIT Investigators
YR 2023
UL http://medrxiv.org/content/early/2023/03/17/2023.03.15.23287338.abstract
AB Background The effectiveness of endovascular thrombectomy (EVT) has been proven even in patients with large cerebral infarction in early time window. However, the association of the time course with the treatment effect is unknown. The aim of this analysis was to evaluate the influence of the time course from stroke onset to reperfusion on the therapeutic effect of EVT.Methods The subjects were patients with occlusion of large vessels and sizable strokes on imaging (ASPECTS 3 to 5) in RESCUE-Japan LIMIT (a multicenter, randomized clinical open-label trial of EVT vs. medical care alone). In the current analysis, the clinical and time course characteristics associated with a favorable outcome (modified Rankin Scale (mRS) 0-2 and 0-3 at 90 days) were examined in patients treated with EVT.Results The analysis included 71 patients (median age, 77 years; median NIHSS score on admission, 21). Occlusion sites were the internal carotid artery (48%), M1 segment of the middle cerebral artery (72%) and tandem lesions (20%). Of these patients, 23 (32%) had mRS 0-3 and 12 (17%) had mRS 0-2 at 90 days. In multivariate analysis, there were independent associations of onset to reperfusion time (OR, 0.991; 95% CI, 0.984-0.999, P = 0.01) and puncture to reperfusion time (OR, 0.952; 95% CI, 0.917-0.988, P < 0.001) with mRS 0-3 at 90 days, and of puncture to reperfusion time (OR, 0.930; 95% CI, 0.872-0.991, P = 0.004) with mRS 0-2 at 90 days.Conclusions Earlier reperfusion was related to a favorable outcome in patients with acute large vessel occlusion with a large ischemic region. Onset to reperfusion time and especially puncture to reperfusion time were independently associated with a favorable outcome. These results suggest the importance of timing and uninterrupted EVT in this patient population.Competing Interest StatementDr Sakai reports research grants from Biomedical Solutions, Medtronic, and Terumo; lecturer fees from Asahi-Intec, Biomedical Solutions, Medtronic, and Terumo; and membership on the advisory boards for Johnson & Johnson, Medtronic, and Terumo outside the submitted work. Dr Yamagami discloses research grants from Bristol Myers Squibb and lecturer fees from Stryker, Medtronic, Terumo, Johnson & Johnson, Biomedical Solutions, and Medico's Hirata during the conduct of the study; and membership of the advisory boards for Daiichi Sankyo, grants from Bristol Myers Squibb, and personal fees from Daiichi Sankyo outside the submitted work. Dr Toyoda reports lecturer fees from Otsuka, Novartis, Bayer, Daiichi Sankyo, Bristol Myers Squibb, and Abbott Medical. Dr Matsumaru reports lecturer fees from Medtronic, Stryker, Terumo, Johnson & Johnson, Kaneka, and Jimro during the conduct of the study and personal fees from EP Medical Consulting outside the submitted work. Dr Matsumoto reports lecturer fees from Kaneka, Medico's Hirata, Fuji Systems, GE Healthcare, Otsuka, Takeda, Century Medical, Terumo, Medtronic, and Stryker. Dr Kimura reports research grants from CSL Behring, EP-CRSU, Amgen Astellas BioPharma, Alexion, Eisai, Kyowa Kirin, Daiichi Sankyo, Teijin, Medtronic, Bristol Myers Squibb, Bayer, Boehringer-Ingelheim, and Helios and lecturer fees from Daiichi Sankyo, Boehringer Ingelheim, Bristol Myers Squibb, Bayer, Takeda, Medtronic, Otsuka, Alexion, Nippon, Chugai, Kyowa Kirin, Abbott, Shire PLC, Sanofi, CSL Behring, Novartis, Toa Eiyo, Medico's Hirata, and Helios. Dr Inoue reports lecturer fees from Bayer, Bristol Myers Squibb, and Medico's Hirata and manuscript fees from Gakken and Hokuryukan. Dr Uchida reports lecturer fees from Daiichi Sankyo, Bristol Myers Squibb, Stryker, and Medtronic during the conduct of the study. Dr Sakakibara reports manuscript fees from Medicus Shuppan during the conduct of the study. Dr Morimoto reports lecturer fees from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Japan Lifeline, Kowa, Toray, and Tsumura; manuscript fees from Bristol Myers Squibb and Kowa; and serving on advisory boards for Novartis and Teijin. Dr Yoshimura reports research grants from Stryker, Siemens Healthineers, Bristol Myers Squibb, Sanofi, Eisai, Daiichi Sankyo, Teijin Pharma, Chugai Pharmaceutical, Healios, Asahi Kasei Medical, Kowa, and CSL Behring and lecturer fees from Stryker, Medtronic, Johnson & Johnson, Kaneka, Terumo, Biomedical Solutions, Boehringer-Ingelheim, Daiichi Sankyo, Bayer, and Bristol Meyers Squibb during the conduct of the study. No other disclosures were reported.Clinical TrialNCT03702413Funding StatementN/AAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol and consent forms were approved by the institutional review boards at Hyogo College of Medicine and all participating hospitals.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not Applicableyes